Clinical Trial Update: Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for single-dose intravesical apaziquone after TURBT in noninvasive bladder cancer patients; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Apaziquone (apaziquone)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-08-15